Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER). Lu F, Lv C, Yang X, Zhuo M, et al. Lung Cancer 2025;206:108676.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lu F, Lv C, Yang X, Zhuo M, et al. Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER). Lung Cancer 2025;206:108676.
PMID: 40706271